Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 9/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23674743 | 0.94 | LTA4H (0.37) | CYP2D6CYP19A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL126770 | 0.90 | NPC1 (0.39) | CYP2D6CYP19A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL128768 | 0.82 | — | — | |
| SCHEMBL2067626 | 0.80 | LSS (0.40) | CYP2D6CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL29108987 | 0.78 | — | — | |
| SCHEMBL2067243 | 0.78 | ALDH1A1 (0.38) | GAAPDE5A | |
| SCHEMBL2478733 | 0.78 | CHRNB2 (0.44) | CYP2D6CYP2C19LTA4HMAPT | |
| SCHEMBL2574560 | 0.74 | — | — | |
| SCHEMBL8922169 | 0.73 | LMNA (0.40) | CYP2D6CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL126131 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312337-B2 | Oxadiazoles and their manufacture | EASTMAN KODAK COMPANY (US) | 2007-12-25 | — | — | US | claimed |
| US-7268235-B2 | Method for preparation of N-pyrazolylamidoximes | EASTMAN KODAK COMPANY (US) | 2007-09-11 | — | — | US | claimed |
| US-20060074245-A1 | Method for preparation of N-pyrazolylamidoximes | EASTMAN KODAK COMPANY | 2006-04-06 | — | — | US | claimed |
| US-20060069262-A1 | Oxadiazoles and their manufacture | EASTMAN KODAK COMPANY | 2006-03-30 | — | — | US | claimed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| CN-101374844-A | Pyrrolopyridazinone compound | UBE INDUSTRIES (JP) | 2009-02-25 | — | — | CN | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| US-7312337-B2 | Oxadiazoles and their manufacture | EASTMAN KODAK COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7268235-B2 | Method for preparation of N-pyrazolylamidoximes | EASTMAN KODAK COMPANY (US) | 2007-09-11 | — | — | US | disclosed |
| US-20060074245-A1 | Method for preparation of N-pyrazolylamidoximes | EASTMAN KODAK COMPANY | 2006-04-06 | — | — | US | disclosed |
| US-20060069262-A1 | Oxadiazoles and their manufacture | EASTMAN KODAK COMPANY | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069262-A1 | Oxadiazoles and their manufacture | OXA1L, CYP1B1, OXER1 | CYP2D6 90/4885CYP19A1 57/4885CYP2C9 20/4885 |
| US-20060074245-A1 | Method for preparation of N-pyrazolylamidoximes | KCNH1, KCNJ2, KCNH2 | CYP2D6 64/4885CYP19A1 1044/4885CYP2C9 30/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | CYP2D6 10/4885CYP19A1 527/4885CYP2C9 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.